EZH2抑制剂使乳腺癌对HER2激酶抑制剂通过对YAP和亲细胞灭绝调节者的合作作用来提高敏感性
Naiara Perurena1, Marina Watanabe1, Amy E Schade1
1Brigham and Women's Hospital and Harvard Medical School Boston United States.
Cancer research
|January 6, 2026
概括
EZH2 抑制剂通过表观遗传修饰重新编程 HER2+ 乳腺瘤. 这提高了HER2向治疗的有效性,并通过上调BMF基因来克服耐药性.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- HER2阳性 (HER2+) 乳腺癌占病例的20%.
- 现有的针对HER2的疗法面临着新的或获得的耐药性挑战.
- 转移性HER2+乳腺癌仍然是一个重大的临床挑战.
研究的目的:
- 研究EZH2抑制剂在克服对HER2向疗法的耐药性的作用.
- 阐明HER2+瘤中耐药性背后的表观遗传机制.
- 探索涉及EZH2抑制剂和HER2激酶抑制剂的组合策略.
主要方法:
- 使用HER2+乳腺癌模型进行体外和体内研究.
- 评估EZH2抑制剂对表观遗传修饰 (H3K27me3) 的影响.
- 对药物治疗反应中的基因表达 (BMF) 和蛋白质复合相互作用 (YAP/TEAD) 的分析.
主要成果:
- EZH2 抑制剂通过减少 H3K27me3.3 逆转了亲细胞灭绝基因 BMF 的表观遗传沉默.
- 虽然单独抑制EZH2导致YAP/TEAD结合,但HER2激酶抑制剂破坏了这个复合体,上调BMF.
- 用EZH2抑制剂和HER2激酶抑制剂或YAP/TEAD抑制的联合治疗,在耐药细胞中强烈诱导了细胞亡.
结论:
- 在HER2+瘤中,EZH2和YAP/TEAD协调调节BMF表达.
- EZH2 抑制剂通过重编程表观遗传环境,使 HER2+ 瘤对 HER2 激酶抑制剂产生敏感性.
- 这一策略显示出增强杀死耐药和残留的HER2+乳腺癌细胞的潜力.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
2.3K
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
11.5K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
